Cancer Research Institute Grants

  • Slingluff, Craig L. C.L. (PI)
  • Hamouda, Danae D. (CoPI)
  • Gaughan, Elizabeth E. (CoPI)
  • Puzanov, Igor I. (CoPI)
  • Shirai, Keisuke K. (CoPI)
  • Kruse, Megan M. (CoPI)
  • Lowe, Michael M. (CoPI)
  • Bhardwaj, Nina (CoPI)

Project Details

Description

Dr. Craig L. Slingluff Jr. serves as the vice-chair for research in the Department of Surgery at UVA Health, director of the UVA Cancer Center Human mmune Therapy Center, co-chair of the Melanoma Committee of ECOG, and a surgical oncologist. He is currently one of the two study chairs of the clinical trial 'A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers' (NCT02643303). This study examines combinations of two checkpoint immunotherapies, plus an immune-stimulating adjuvant, in a wide variety of patients diagnosed with breast cancer, sarcoma, head and neck cancer, lymphoma, melanoma, bladder cancer, kidney cancer, prostate cancer, among other types of cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway. The adjuvant, poly ICLC, promotes an immune system response similar to that of vaccines.
StatusActive
Effective start/end date1/01/15 → …

Funding

  • Cancer Research Institute

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.